Veru (VERU) Income from Non-Controlling Interests (2012 - 2024)
Veru's (VERU) quarterly Income from Non-Controlling Interests came in at $81373.0 in Q3 2024, down 46.0% year-over-year from $150689.0 in Q4 2023, and up 2629.72% quarter-over-quarter from $2981.0 in Q2 2024.
Powered by 
Analysis
Veru (VERU) Income from Non-Controlling Interests (2012 - 2024) Analysis & Trends
Veru (VERU) has reported Income from Non-Controlling Interests for 13 consecutive years, with $81373.0 the latest figure, recorded in Q3 2024.
- On a quarterly basis, Income from Non-Controlling Interests fell 46.0% year-over-year to $81373.0 in Q3 2024; TTM through Sep 2024 was $84295.0, a 31.38% decrease from a year earlier, with the FY2024 full-year figure at $84295.0, down 31.38% from the prior year.
- Income from Non-Controlling Interests was $81373.0 for Q3 2024 at Veru, up from $2981.0 in the prior quarter.
- Over five years, Income from Non-Controlling Interests peaked at $150689.0 in Q3 2023 and troughed at -$73061.0 in Q3 2022.
- A 5-year average of $23766.4 and a median of $1131.0 in 2020 frame the typical range for Income from Non-Controlling Interests.
- Across the five-year window, Income from Non-Controlling Interests jumped 5726.64% in 2021 and tumbled 6852.4% in 2022, its largest moves.
- Over 5 years, Income from Non-Controlling Interests stood at $1952.0 in 2020, then jumped by 5726.64% to $113736.0 in 2021, then sank by 100.1% to -$118.0 in 2022, then jumped by 80.51% to -$23.0 in 2023, then soared by 353895.65% to $81373.0 in 2024.
- The last three Income from Non-Controlling Interests figures came in at $81373.0 (Q3 2024), $2981.0 (Q2 2024), and -$36.0 (Q1 2024), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | - |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | 3.00 Mn |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | -2.00 Mn |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | -7.00 Mn |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 10.00 Mn |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | 39.52 Mn |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | - |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | - |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | - |
| 10 | Veru | 57.86 Mn | 32.06 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2024 | 81,373.00 |
| Jun 30, 2024 | 2,981.00 |
| Mar 31, 2024 | -36.00 |
| Dec 31, 2023 | -23.00 |
| Sep 30, 2023 | 150,689.00 |
| Jun 30, 2023 | -21,219.00 |
| Mar 31, 2023 | -6,500.00 |
| Dec 31, 2022 | -118.00 |
| Sep 30, 2022 | -73,061.00 |
| Jun 30, 2022 | 56,640.00 |
| Mar 31, 2022 | 38,794.00 |
| Dec 31, 2021 | 113,736.00 |
| Sep 30, 2021 | 1,082.00 |
| Jun 30, 2021 | 50,538.00 |
| Mar 31, 2021 | -864.00 |
| Dec 31, 2020 | 1,952.00 |
| Sep 30, 2020 | 595.00 |
| Jun 30, 2020 | 53,872.00 |
| Mar 31, 2020 | 1,131.00 |
| Dec 31, 2019 | 2,730.00 |